EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial

Kyung-Hwa Park iD, Jongtak Jung iD, Sung Un Shin, Su Jin Jeong, Dae Won Park, Dong-Min Kim, Seong Jin Choi, Song Mi Moon, Jeong Su Park, Kyoung-Ho Song iD, Eu Suk Kim iD, Young Lag Cho und 3 weitere

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.03361-25 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Kyung-Hwa Park und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Methicillin-Resistant Staphylococcus aureus, Oxazolidinones. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a serious clinical challenge due to limited treatments and high mortality. We conducted both preclinical and clinical studies to assess the potential role of delpazolid in combination with vancomycin. Synergistic effects of delpazolid with vancomycin or daptomycin were evaluated in vitro using checkerboard and time-kill assays, and in vivo using a Galleria mellonella model. A multicenter, double-blind, randomized, Phase IIa trial was conducted at six Korean hospitals between 26 April 2022 and 18 March 2024. Patients with MRSA bacteremia were randomized 1:1 to receive vancomycin monotherapy or vancomycin plus delpazolid for 14 to 42 days. The primary outcome was overall cure at day 14 (microbiological clearance and symptom resolution). Secondary endpoints included safety, adverse events, and delpazolid pharmacokinetics. In vitro checkerboard assays showed no interaction between delpazolid and vancomycin or daptomycin, while time-kill assays revealed antagonism only when delpazolid was combined with vancomycin. In the Galleria mellonella model, combination therapy improved survival over monotherapy. In the clinical study, 40 patients were enrolled, 38 received ≥1 dose (safety set), and 34 (monotherapy: 19; combination: 15) were included in the full analysis set. On day 14, overall cure was 52.6% in the monotherapy and 60.0% in the combination group ( P = 0.6675). Adverse event rates were similar across groups, with no significant safety concerns. In pharmacokinetic analyses, delpazolid showed favorable plasma levels when co-administered. These preliminary findings warrant further investigation in adequately powered trials to define the role of delpazolid plus vancomycin in the treatment of MRSA bacteremia. CLINICAL TRIALS The study is registered with ClinicalTrial.gov as NCT05225558 . IMPORTANCE Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia presents a serious clinical challenge due to limited treatments and high mortality. This study evaluated the potential role of delpazolid, an oral oxazolidinone, in combination with vancomycin for MRSA bacteremia. Preclinical studies demonstrated delpazolid’s antimicrobial activity comparable to vancomycin and daptomycin, and in the Galleria mellonella infection model, combination therapy significantly improved survival rates over monotherapy. The early-terminated Phase IIa clinical study showed that the combination regimen had an acceptable safety profile, with no apparent increase in adverse events compared to vancomycin monotherapy. While overall cure rates and bacteremia clearance were numerically higher in the combination group, these differences were not statistically significant. These preliminary findings underscore the need for larger, adequately powered clinical trials to clarify the clinical role of delpazolid combination therapy in MRSA infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacteremiaMethicillin-Resistant Staphylococcus aureusOxazolidinonesStaphylococcal InfectionsVancomycinAdultAgedAnimalsFemaleHumansMaleMiddle AgedDouble-Blind MethodDrug Therapy, CombinationMicrobial Sensitivity TestsTreatment Outcome

Stichwörter der Autor:innen

MRSA bacteremiaclinical trialcombination therapydelpazolidvancomycin

Substanzen

Anti-Bacterial AgentsOxazolidinonesVancomycindelpazolid

Autor:innen und Institutionen

  • Department of Infectious Diseases, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.
  • Division of Infectious Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
  • Division of Infectious Diseases, Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seodaemun-gu, Korea.
  • Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Chosun University Hospital, Gwangju, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

ORCID-Profile: Kyung-Hwa Park, Jongtak Jung, Kyoung-Ho Song, Eu Suk Kim, Seongman Bae, Hong Bin Kim

Zitieren

APA

Park, K. H., Jung, J., Shin, S. U., Jeong, S. J., Park, D. W., Kim, D. M., Choi, S. J., Moon, S. M., Park, J. S., Song, K. H., Kim, E. S., Cho, Y. L., Bae, S., Kim, H. B., & Korea INfectious Diseases (KIND) Study Group (2026). Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03361-25

Vancouver

Park KH, Jung J, Shin SU, Jeong SJ, Park DW, Kim DM, et al. Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial. Microbiology Spectrum. 2026. doi:10.1128/spectrum.03361-25

BibTeX
@article{Park2026,
  author = {Park, Kyung-Hwa and Jung, Jongtak and Shin, Sung Un and Jeong, Su Jin and Park, Dae Won and Kim, Dong-Min and Choi, Seong Jin and Moon, Song Mi and Park, Jeong Su and Song, Kyoung-Ho and Kim, Eu Suk and Cho, Young Lag and Bae, Seongman and Kim, Hong Bin and Korea INfectious Diseases (KIND) Study Group, Korea INfectious Diseases (KIND) Study Group},
  title = {Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.03361-25}
}
Kostenlos starten →